42:I[185,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SendEmailButton"] 44:I[63625,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"AddToLibraryButton"] 45:I[29721,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ShareButton"] 46:I[58016,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ProcessEpisodeButton"] 47:I[45269,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/2aeejfufo02km.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/2qm8z4gyuajgj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SignupCTA"] 3a:["$","time",null,{"dateTime":"2026-07-16T21:03:11.000Z","children":"July 16, 2026"}] 3b:["$","span",null,{"aria-hidden":true,"children":"·"}] 3c:["$","span",null,{"children":"00:04:33"}] 43:T499,

Today's biggest winners and losers in the stock market, a look at the notable movers:
On this episode of Stock Movers:

- Netflix (NFLX) shares decline as much as 6.5% in post-market trading after the streaming service forecast earnings per share for the third quarter and guidance that missed the average analyst estimate.

- Eli Lilly (LLY) agreed to buy AtaiBeckley (ATAI) for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine. Lilly will pay $6.75 a share in cash plus as much as another $2.50 a share if drug-development milestones are met, according to a statement Thursday.

-Abbott (ABT) shares surge as much as 14%, the most intraday since July 2002, after the healthcare company boosted its adjusted earnings per share forecast for the full year, with the updated outlook coming in ahead of the average estimate from analysts. It also posted adjusted profit and net sales for the second quarter that topped expectations. Analysts view the overall results as better than anticipated.

See omnystudio.com/listener for privacy information.